Phase 3 Studies of Prevnar 13 for Pneumococcal Vaccination in Older Adults - ONA

Links shared publicly online about this topic.

  • 305
    total visits

Phase 3 Studies of Prevnar 13 for Pneumococcal Vaccination in Older Adults - ONA

oncologynurseadvisor.com

Pfizer Inc announced results from two Phase 3 studies of Prevnar 13 (Pneumococcal 13-valent conjugate vaccine [diphtheria CRM197 protein]) for vaccination in adults 50 years.

View full resource at oncologynurseadvisor.com

Tags: Vaccination, Diphtheria, Pneumococcal Vaccine, Phase 3 Clinical Trial, Healthy Aging, Vaccine, Prevnar, Pfizer

  • Share

Most Recently Shared on May 9, 2011 at 7:29 pm By:

ONAcom OncologyNurseAdvisor

Phase 3 Studies of Prevnar 13 for Pneumococcal Vaccination in Older Adults http://goo.gl/fb/75RVH

1 year ago...

Phase 3 Study Update of Prevnar 13 for Pneumococcal Vaccination in Older Children and Adolescents - MPR

empr.com — “Pfizer announced that data from a Phase 3 study of Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) met all study endpoints, showing immunogenicity and establishing a safety profile in children and adolescents aged 5-17 years.View full resource at empr.com

  • View Related
  • Share

Most Recently Shared on March 12, 2012 at 2:26 pm By:

eMPR MPR Medical Publisher

Phase 3 Study Update of #Prevnar 13 for Pneumococcal #Vaccination in Older Children and Adolescents http://t.co/lK3eB0L1 #immunization

2 months ago...

Phase 3 Studies of Prevnar 13 for Pneumococcal Vaccination in Older Adults - MPR

empr.com — “Pfizer Inc announced results from two Phase 3 studies of Prevnar 13 (Pneumococcal 13-valent conjugate vaccine [diphtheria CRM197 protein]) for vaccination in adults 50 years.View full resource at empr.com

  • View Related
  • Share

Most Recently Shared on May 9, 2011 at 7:30 pm By:

eMPR MPR Medical Publisher

MPR News: Phase 3 Studies of Prevnar 13 for Pneumococcal Vaccination in Older Adults: Pfizer Inc announced resul... http://bit.ly/iMHFNI

1 year ago...

Phase 3 Studies of Prevnar 13 for Pneumococcal Vaccination - MPR

empr.com — “Pfizer Inc announced results from two Phase 3 studies of Prevnar 13 (Pneumococcal 13-valent conjugate vaccine [diphtheria CRM197 protein]) for vaccination in adults 50 years.View full resource at empr.com

  • View Related
  • Share

Most Recently Shared on May 9, 2011 at 2:57 pm By:

eMPR MPR Medical Publisher

MPR News: Phase 3 Studies of Prevnar 13 for Pneumococcal Vaccination: Pfizer Inc announced results from two Phas... http://bit.ly/iIfHg4

1 year ago...

Advertisement